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ABSTRACT 
Background Systemic lupus erythematosus (SLE) is associated with adverse pregnancy 
outcomes overall. 
 
Objective To examine the outcomes for women with SLE in a pregnancy subsequent to a 
first birth with an adverse outcome. 
 
Methods A population-based cohort study was carried out of 794 577 deliveries to 532 612 
women giving birth in New South Wales, Australia from 2001 to 2009. Data were obtained 
from longitudinally linked birth records and hospital records. 
 
Results 675 women had a diagnosis of SLE in the study period (prevalence 127 per 100 
000 childbearing women). Of 177 women who had a first nulliparous birth and subsequent 
pregnancy, 10 (5.6%) had a perinatal death in the first pregnancy, and of these women, 9 
(90%) had a baby discharged home alive in the second pregnancy. Of the 167 women 
whose first-birth infants survived, second pregnancy outcomes included: 18 (11%) admission 
for spontaneous abortion, 1 perinatal death (0.6%) and 148 (89%) infants discharged home. 
Two women had a thromboembolic event in their first pregnancy but had no thromboembolic 
event in the second. Two women had thromboembolic events in second pregnancies only. 
 
Conclusion Women with SLE are at high risk of adverse pregnancy outcomes. However, 
those who have a perinatal death in their first pregnancy can expect a live birth for a 
subsequent pregnancy. 
INTRODUCTION 
Systemic lupus erythematosus (SLE) is a multisystem 
autoimmune connective tissue disease that predominantly affects women of childbearing 
age. A review of prevalence studies, mainly from the 1990s, reported rates for Caucasian 
populations ranging from 50 to 130/100 000 women.1 
 
A systematic review and meta-analysis of pregnancy outcomes in women with SLE 
published in 2010 included 37 studies of 2751 pregnancies in 1842 women.2 The majority of 
studies (n=29) were small case series, with the largest including 203 women with 267 
pregnancies.3 Compared with women without SLE, women with SLE have greater rates of 
pregnancy complications, including higher rates of pre-eclampsia, gestational hypertension, 
eclampsia and lupus fl are.2 These findings have been confirmed in large studies of hospital 
records; however, hospital database studies have been limited by an inability to track 
longitudinally individuals with one or multiple hospital admissions.3 4 The hospitalisation 
studies also suggest that women with SLE have higher rates of caesarean section and 
higher rates and duration of hospital admission.3 4 Fetal or neonatal complications in 
women with SLE compared with those without SLE have been widely reported and include 
spontaneous abortion, intrauterine growth restriction, preterm birth, stillbirth and neonatal 
death, as well as congenital heart block in women with autoantibodies to anti- SSA/Ro and 
anti-SSB/La.2 More recent studies have suggested improved fetal and neonatal outcomes 
compared with earlier studies.5 
 
Outcomes for women with SLE in a pregnancy subsequent to a first birth with an adverse 
outcome have not been reported. This lack of information for counselling arose in 
discussions subsequent to a woman with SLE presenting with a first pregnancy stillbirth. 
Therefore the aim of our study was to determine the second pregnancy incidence and 
recurrence of perinatal mortality and maternal morbidity among women with SLE. 
 
SUBJECTS AND METHODS 
Study population 
The study population included all women who gave birth in New South Wales (NSW), 
Australia during 2001–8. NSW is the most populous Australian state with a population of ~ 
6.9 million and one-third of all Australian births (~95 000 a year) in over 100 hospitals, 
ranging from small rural hospitals to tertiary centres. Australian healthcare includes a mixture 
of public and private care; all women are covered by national health insurance, which 
provides access to hospital and specialist care but about one-third take out private insurance 
for obstetric care. 
 
Data sources 
Data were obtained from longitudinally linked population datasets for births during the years 
2001–9: the NSW Perinatal Data Collection (PDC), a population-based surveillance system 
of all births (≥20 weeks’ gestation or ≥400 g birth weight) and the NSW Admitted Patient 
Data Collection (APDC), an administrative database of all public and private hospital 
admissions in NSW. The separate datasets were linked using probabilistic linkage methods 
and were made available to the researchers as deidentified data.6 Longitudinal linkage 
allows identification of individuals with multiple hospital records and consecutive 
pregnancies. The linkage and use of the data was approved by the NSW Population and 
Health Services Research Ethics Committee. The PDC records were used to identify 
nulliparous women with a first birth of ≥20 weeks’ gestation during 2001 to 2008 and to 
identify subsequent pregnancies and births up until 31 December 2009. 
 
SLE diagnosis 
Women with SLE were identified from the APDC, based on a diagnosis of SLE made in the 
medical records by an attending doctor and subsequently coded into the discharge 
summary. More than 20 diagnoses and procedures for each hospital admission can be 
recorded, and are coded according to the International Classifi \cation of Diseases version 
10 Australian modifi \cation (ICD10). SLE (ICD10 code M32) could have appeared as the 
primary admitting diagnosis or as a comorbid condition for nonpregnancy or pregnancy-
related admissions. 
 
SLE is reliably identified in hospital data when the diagnosis is recorded in the medical 
record. A US validation of 234 inpatients with SLE found administrative data to ascertain 
89% of cases with few false positives (positive predictive value 89%).7 This is consistent 
with three local validation studies of hospital data identification of connective tissue 
disorders, which found reporting sensitivities of 85–100% and specificities of 99.9–100%.8–
10  
Pregnancy factors 
Linked APDC discharge summaries were available from July 2000 to December 2009 and 
included pregnancy and non-pregnancy admissions. Only spontaneous abortions which 
result in admission to hospital can be identified in the APDC. The APDC was also used to 
identify conditions representing potential nephritis or renal involvement during pregnancy, 
including glomerular disorders, tubulo-interstitial disorders, pre-eclampsia or eclampsia, 
renal biopsy, renal failure or dialysis. The APDC and PDC were used to identify women who 
had pregnancy hypertension (including gestational hypertension, pre-eclampsia and 
eclampsia), diabetes (pre-existing and gestational) and obstetric haemorrhage (antepartum 
or postpartum) and thromboembolic events (puerperal deep vein thrombosis, pulmonary 
embolism or cerebral venous thromboembolism), antenatally and up to 42 days after 
delivery. Transfusion was identified from procedure codes recorded in the discharge 
summaries, and included blood products such as fresh frozen plasma or platelets, as well as 
packed red blood cell transfusion. Gestational age at delivery and infant birthweight were 
recorded in the PDC. Infant discharge status (stillbirth, neonatal death or discharge alive) 
was ascertained from the PDC and the APDC. Stillbirth was defined as a fetal death of at 
least 20 weeks’ gestation or 400 g birth weight. Neonatal death was defined as a death 
during the first 28 days or where the infant was never discharged home alive. Perinatal 
deaths include both stillbirths and neonatal deaths. Small for gestational age was defined as 
below the third birth weight centile for gestational age and infant sex.11 Only factors that we 
have previously shown to be reliably reported in the population health data were included in 
the analyses.8 9 12–15 
 
Analysis 
The initial analysis compared pregnancy outcomes in mothers ever diagnosed with SLE with 
mothers without SLE. Further analyses were limited to nulliparous women with a record of 
SLE before their second consecutive birth, as our primary aim is to enable counselling of 
women with SLE and a second pregnancy. We used frequency distributions and contingency 
table analyses to describe the pregnancies and outcomes experienced by women with and 
without SLE. The relationship between SLE and maternal factors and pregnancy outcomes 
is reported as relative risk (RR) with 95% CI. 
 
RESULTS 
From 2001 through 2009 there were 794 577 deliveries to 532 612 women, including 1058 
deliveries to 675 women with an SLE diagnosis recorded during the study period (Figure 1). 
This gives a prevalence rate of SLE of 127 per 100 000 childbearing women. Compared with 
women without SLE, the rate of adverse outcomes in women with SLE ever recorded was 
increased (table 1). There were no maternal deaths among women with SLE.  Figure 1 is a 
schematic diagram of how the study population was derived. There were 350 nulliparous 
women with a first birth and who ever had an admission with SLE in the study period; for 234 
(67%) a diagnosis of SLE was recorded before their first delivery. The rate of stillbirth in that 
first birth was higher in the women whose diagnosis was not recorded by the time of that first 
birth than in those who already had a diagnosis (7% vs 3%) but the risk was not statistically 
significant: RR=2.7 (0.95–7.6). The neonatal death rate was 1% both for diagnosed and 
undiagnosed women. For 37 of these women the earliest recorded diagnosis of SLE was 
after a second birth; they were excluded from further analyses. These excluded women were 
older at the time of their first recorded diagnosis of SLE (31.3 years (SD 4.7)) compared with 
the 313 women who remained in the analysis (29.8 years (SD 5.3)). The 37 women who 
were not diagnosed until after their second pregnancy also had a spontaneous abortion rate 
of 30% for that second pregnancy. 
 
Maternal and infant characteristics of the 313 women who remained in the analysis are 
shown in table 2. The median period between first and second pregnancies was 2.3 years 
(IQR 1.6–3.0); however, women with a first birth in the latter part of the study period had less 
time in follow-up for a second birth. Among the subgroup of women whose first birth was in 
2001–4, 119/172 (69%) recorded a second pregnancy. 
 
The birth outcomes for the 177 women who had a second pregnancy are shown in table 3. 
Of the 10 women who had a stillbirth or neonatal death in their first pregnancy, nine (90%) 
had a live-born infant who was discharged home in their second pregnancy while one 
woman had a spontaneous abortion at ≥14 weeks. Among the 167 mothers whose firstborn 
was discharged home alive there was only one stillbirth and no neonatal deaths in the 
second pregnancy but there were 18 spontaneous abortions (11%). None of the 
spontaneous abortions were coded as ≥14 weeks’ gestation, although two were of unknown 
gestation. None of these first-born infants, but two of the second-born infants, were 
diagnosed with atrioventricular block. 
 
Table 4 shows the occurrence and recurrence of serious maternal adverse events in the first 
and second pregnancies. The persistence or recurrence of renal impairment in a second 
pregnancy was common but obstetric haemorrhage recurrence was not. 
 
DISCUSSION 
This is the largest cohort study of SLE in pregnancy that includes data on infant outcomes 
such as gestational age and size at birth; the infants of mothers with SLE had significantly 
increased risks for growth restriction, preterm birth and perinatal mortality. We report second 
birth outcomes for women with SLE, and the outlook for a baby surviving to discharge home 
is generally favourable. However, women who had only one birth were more likely to have 
had renal impairment than the women who went on to have a second birth, which may 
indicate differential severity and selective fertility. 
 
The rate of perinatal death in first births (4.8% in the cohort of 313 women) and in the 
subsequent pregnancies (<1%) in our study are lower than the 6.1% perinatal death rate for 
SLE pregnancies calculated in a recent meta-analysis.2 A majority of the births in that meta-
analysis occurred in previous decades and our results may partly reflect improvements in the 
management of SLE, and of neonates generally, for our recent cohort. Only 11% of the 
second pregnancies in our study resulted in a spontaneous abortion, compared with 16.0% 
in that same meta-analysis. In the Johns Hopkins first trimester cohort study, 9% of the 
pregnancies resulted in spontaneous abortion, of which 5% were before 10 weeks.16 
Coding for spontaneous abortions was limited to before and after 14 weeks in our study, so 
we cannot make a direct comparison by gestation. Our results are consistent with a high rate 
of early spontaneous abortion, as all but one of the spontaneous abortions assigned a 
gestational range occurred before 14 weeks. The women in our study had similar rates of 
pregnancy hypertension and stroke to women in the large US study of over 13 000 
hospitalisations which used both SLE and pregnancy-related discharge codes, but we found 
higher rates of thromboembolic events and obstetric haemorrhage.17 However, our event 
counts included all those that occurred in antenatal admissions and admissions up to 6 
weeks postpartum, not just admissions coded as pregnancy related.17 
 
In women with SLE, stillbirth or neonatal morbidity may be caused by complete 
atrioventricular heart block, secondary to autoantibodies to SSA/Ro or SSB/La. The rate of 
congenital heart block in the infants of women with autoantibodies is reported to be 1–5%.18 
There were three infants with neonatal heart block within the entire study cohort which is a 
rate of 0.6%; however, the rate or level of autoantibodies in the study population is not 
known. The optimal screening and or treatment strategy for women with autoantibodies to 
SSA/Ro or SSB/La is also not known, and although some authors recommend weekly fetal 
echocardiography ultrasound surveillance, with treatment with steroids for those with a 
prolonged PR interval, the screening and treatment strategy in NSW during the time period 
is also not known.19 
 
Some studies report that women with SLE have lower live birth rates and lower pregnancy 
rates than women without SLE.20 21 Women with SLE in our population were more likely to 
have used assisted reproduction methods (RR=1.42) but the actual proportion was not large 
(4.8% vs 3.4% in women without SLE). Our study does not capture women with SLE who 
never carried a pregnancy to ≥20 weeks’ gestation. It is not known whether a lower 
pregnancy rate among women with SLE might be related to adverse pregnancy outcomes, 
infertility, spontaneous abortion, personal relationship problems and/or a deliberate decision 
to limit family size, possibly because of the women’s quality of life due to the disease. The 
rate of second pregnancy within the study period was 69%, comparable to that of the 
general population. 
 
The recurrence analysis was limited to women with first birth and second pregnancy, in order 
to have a homogeneous study population.22 For some women, their first recorded diagnosis 
of SLE was after their first birth, rather than before. Poor fetal outcomes have been seen in 
pregnancies complicated by SLE before the clinical diagnosis of the disease, as was found 
in this study.23 For those attempting a second pregnancy, renal impairment was common, 
obstetric haemorrhage was higher than in the general maternity population and 
thromboembolic events and perinatal death did not reoccur, although numbers were small. 
 
The strength of this study is that it is a recent, large, population- based study in which 
perinatal factors including perinatal mortality, gestational age and birth weight are reliably 
reported. 8 9 14 15 Data were collected as part of a population surveillance system, and 
thus the potential for bias is reduced, as all childbearing women are included, regardless of 
outcome. The linkage allowed us to track longitudinally women rather than simply tabulate 
admissions, which can result in multiple counting of those who have many hospital 
admissions. Furthermore, validation studies find SLE to be reliably identified in hospital 
data7–10 and the SLE prevalence in our study of 127 per 100 000 childbearing women is 
consistent with expectation.1 Of note, however, is that the timing of the SLE diagnosis is 
based on the first hospital admission when the SLE diagnosis was recorded. One of the 
limitations in this study is the lack of detailed clinical data, including treatment information. A 
prospective cohort study presented in abstract form, of 333 women with SLE in pregnancy, 
found that the following baseline variables were associated with poor pregnancy outcome: 
higher SLE disease activity index, high titre antiphospholipid antibody and higher median 
uric acid levels and an increase over baseline of the SLE disease activity index.24 Other 
studies have found that women with lupus nephritis have worse pregnancy outcomes.2 25 
We could not determine the degree of underlying renal impairment or hypertension, or SLE 
disease activity or the presence of antiphospholipid antibodies. 
 
Spontaneous abortion rates may be underestimated in our study, as only spontaneous 
abortions that resulted in hospitalisation can be identified. Additionally, women who never 
carried a pregnancy to 20 weeks or more were not included in our data. The study’s focus is 
on the prospects for pregnancy in women with SLE after a first birth; women with more 
severe forms of SLE may never achieve a first birth of ≥20 weeks’ gestation. 
 
CONCLUSIONS 
In this recent cohort, 69% of women with SLE with at least 5 years’ follow-up went on to 
have a second pregnancy. In second pregnancies to women diagnosed with SLE, 89% 
resulted in infants being discharged home alive, with no recurrence of 
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Figure 1: Study population derivation 
 
 
794,577 births 2001- - 2009 
(532,612 women) 
1058 births to  
675 women with SLE 
793,519 births to  
531,937 women without SLE 
313 first   births*  
2001- - 2008 
136 no 2nd   pregnancy 177   2nd pregnancies  
* Among women with an SLE diagnosis recorded before their 2nd birth   
Table 1. Characteristics of pregnancies to mothers with and without a record of SLE (all pregnancies 
≥ 20 weeks gestation), NSW 2001-2009. 
 SLE pregnancies* 
n=1058 
 (%) 
Pregnancies 
without SLE 
n=793,519 
(%) 
Relative risk 
(95% CI) 
 
Maternal factors    
Age ≥ 35 years 25.0 21.0 1.19 (1.07-1.32) 
Smoking during pregnancy 10.7 14.3 0.75 (0.63-0.89) 
Assisted reproduction (any record) 4.8 3.4 1.42 (1.09-1.86) 
Pregnancy hypertension 19.8 8.7 2.28 (2.02-2.57) 
Diabetes (gestational or pre-existing) 7.4 6.1 1.22 (0.98-1.51) 
Renal impairment 13.2 2.8 4.64 (3.97-5.41) 
One or more antenatal admissions 
 
38.8 21.5 1.81 (1.67-1.95) 
Pregnancy outcomes    
Twins, other multiple pregnancy 1.3 1.6 0.84 (0.50-1.42) 
Preterm (<37 weeks) 
  33-36 weeks 
  <33 weeks 
 
14.7 
8.5 
 
5.0 
1.7 
 
2.92 (2.51-3.40) 
5.03 (4.07-6.23) 
Onset of labour 
  spontaneous 
  induced 
  prelabour caesarean  
 
33.7 
37.6 
28.6 
 
59.0 
25.1 
15.8 
 
1.00 (referent) 
1.77 (1.65-1.89) 
2.17 (2.00-2.36) 
Any caesarean birth 42.3 27.6 1.53 (1.43-1.64) 
Delivery at tertiary referral hospital 48.2 27.2 1.77 (1.66-1.89) 
Antepartum haemorrhage 6.6 3.7 1.78 (1.42-2.23) 
Postpartum haemorrhage 9.4 7.6 1.23 (1.02-1.49) 
Any Thromboembolic event‡ 1.51 0.17 9.11 (5.19-14.9) 
   Pulmonary embolism 
     antepartum 
     puerperal† 
 
0.47 
0.76 
 
0.04 
0.06 
 
13.2 (5.45-31.8) 
13.5 (6.72-27.1) 
   Cerebral event 0.28 0.01 30.8 (9.73-97.6) 
   Puerperal† deep vein thrombosis 0.47 0.08 6.08 (2.53-14.6) 
Transfusion of blood product 
 
3.9 1.3 3.03 (2.24-4.09) 
Infant outcomes    
Small for gestational age (<3rd 
percentile) 
6.4 4.0 1.60 (1.27-2.02) 
Perinatal mortality 3.0 0.8 3.59 (2.55-5.06) 
5-minute Apgar <7 4.7 2.0 2.36 (1.80-3.10) 
Heart block 0.38 0.01 37.5 (13.8-102) 
*    Includes diagnosis after second or later birth 
†    Up to 6 weeks postpartum 
‡    pulmonary embolism, cerebral event (cerebral ischemia or infarction ) or puerperal DVT 
Table 2. Maternal and infant characteristics of women with SLE and a first pregnancy ≥ 20 weeks 
gestation 2001-2008.  
Characteristics of first pregnancy 
≥ 20 weeks gestation 
Women 1st and 2nd 
pregnancies  
n=171 
n (%) 
Women with only 
1st pregnancies 
n=145 
n (%) 
Maternal factors and outcomes   
Maternal age  
   <30 years 
   30-34 years 
   ≥ 35 years  
 
99 (57.9) 
52 (30.4) 
20 (11.6) 
 
68 (46.9) 
37 (25.5) 
40 (27.6)* 
Smoking during pregnancy 11 (6.4) 13 (9.0) 
Antenatal admissions 
  one 
  two or more 
 
38 (22.2) 
25 (14.6) 
 
39 (26.9) 
22 (15.2) 
In vitro fertilisation 10 (5.8) 16 (11.0) 
Twin pregnancy 3† (1.8) 4 (2.8) 
Chronic hypertension 3 (1.8) 7 (4.8) 
Gestational hypertension 35 (20.5) 42 (29.0) 
Preeclampsia 15 (8.8) 24 (16.6)* 
Pregnancy renal impairment†† 19 (11.1) 35 (24.1)* 
Diabetes 10 (5.9) 9 (6.2) 
Lupus  anticoagulant 7 (4.1) 8 (5.5) 
Antepartum/postpartum 
haemorrhage 
17 (9.9) 27 (18.6)* 
Thromboembolic event‡ 1 (0.6) 4 (2.8) 
Mother transferred to ICU 2 (1.2) 2 (1.4) 
Infant outcomes   
Gestational age at birth 
   <34 weeks 
    34-36 weeks 
   ≥37 weeks 
 
20 (11.6) 
20 (11.6) 
131 (76.6) 
 
16 (11.0) 
24 (16.6) 
105 (72.4) 
Spontaneous preterm birth 14 (8.2) 11 (7.6) 
Birthweight (grams: median, IQR) 3110 (2700-3480) 2980 (2410-3420) 
SGA <3rd percentile 14 (8.2) 18 (12.5) 
Perinatal death 11 (6.4) 5 (3) 
*    P<0.05 for chi-squared test of comparison between women with second pregnancies and women 
without 
†    one twin pregnancy resulted in the neonatal death of one twin 
††  preeclampsia, admission with glomerular or tubulo-interstitial disorder, or renal failure 
SGA Small for gestational age 
‡    pulmonary embolism, puerperal DVT, cerebral event 
Table 3.  Infant outcomes of the first pregnancy compared to the second pregnancy among 171 
women with a diagnosis of SLE. 
 Next pregnancy outcome 
First pregnancy (of ≥ 20 weeks) 
infant outcome 
Miscarriage 
n= 9 
n (row %) 
Perinatal death 
(n=1) 
n  (row %) 
Baby discharged home 
(n=161) 
n (row %) 
    
Stillbirth (n=8) 1 (12) 0 (0) 7 (88) 
Neonatal death (n=3) 0 (0) 0 (0) 3 (100) 
Baby discharged home (n=160) 8 (5) 1 (1) 151 (94) 
Gestation <32 weeks  (n=16) 2 (12) 0 (0) 14 (88) 
SGA < 3rd percentile (n=14) 0 (0) 1 (7) 13 (93) 
SGA Small for gestational age 
 
 
Table 4.  Maternal adverse events among 171 women with a subsequent pregnancy 
  Adverse event at next 
birth? 
Maternal adverse events in first 
pregnancy (of ≥ 20 weeks) 
Yes 
n (row %) 
No 
n (row %) 
Pregnancy renal impairment† 
      Yes (n=19) 
      No (n=152) 
 
9 (47) 
10 (7) 
 
10 (53) 
142 (94) 
Antepartum/postpartum 
haemorrhage 
     Yes (n=17) 
     No (n=164) 
 
 
1 (6) 
16 (10) 
 
 
16 (94) 
138 (94) 
Transfusion  
     Yes (n=4) 
     No (n=167) 
 
0 (0) 
6 (4) 
 
4 (100) 
161 (96) 
Thromboembolic event‡ 
     Yes (n=1) 
     No (n=170) 
 
0 (0) 
2 (1) 
 
1 (100 
169 (99) 
† defined as preclampsia, admission with glomerular or tubulo-interstitial disorder, or renal failure 
‡    pulmonary embolism, puerperal DVT, cerebral event 
 
 
 
 
 
